Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.

ABSTRACT:

Background

Despite the widespread use of erythropoietin-stimulating agents (ESAs) to treat anemia in patients undergoing hemodialysis, the relative mortality risks associated with use of different types of ESAs are unknown.

Methods

To compare the mortality risk associated with use of short-acting ESAs versus long-acting ESAs, we conducted a nationwide cohort study of 194,698 hemodialysis patients in Japan who received either a short-acting (epoetin α/β or epoetin κ) or a long-acting (darbepoetin or epoetin β pegol) ESA. Study outcomes were 2-year all-cause and cause-specific mortality. In addition to Cox proportional hazards models, we performed an instrumental variable analysis in which facility-level long-acting ESA prescription rates were taken as the

SUBMITTER: Sakaguchi Y 

PROVIDER: S-EPMC6551773 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature